Progesterone receptor antagonists and the endometrial antiproliferative effect

Seminars in Reproductive Medicine

Volumn 23, Issue 1, 2005, Pages 74-81

  Brenner, Robert M ^a   Slayden, Ov D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Agonist; Androgen receptor; Antagonist; Endometrial antiproliferative effect; Endometrium; Progesterone receptor

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIGESTAGEN; ESTROGEN; FLUTAMIDE;

ANTIPROLIFERATIVE EFFECT; CELL PROLIFERATION; DRUG EFFECT; ENDOMETRIUM; ESTROGEN ACTIVITY; HUMAN; HYALINE DEGENERATION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MACACA; MENSTRUAL CYCLE; MITOSIS RATE; NONHUMAN; OVARIECTOMY; PRIMATE; REPRODUCTION; REVIEW; SPONTANEOUS ABORTION;

ANIMALS; CELL DIVISION; ENDOMETRIUM; FEMALE; HORMONE ANTAGONISTS; HUMANS; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE;

EID: 14744304958     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864035     Document Type: Review

References (50)

1. Spitz IM, Robbins A. Mechanism of action and clinical effects of antiprogestins on the non- pregnant uterus. Hum Reprod Update 1998;4:584-593
2. Leonhardt SA, Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood) 2002;227:969-980
3. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997;48:129-156
4. Bennink H. The Jerusalem declaration on progesterone receptor modulators. Steroids 2000;65:839
5. Philibert D. RU 38486: an original multifaceted antihormone in vivo. In: Agarwal MK, ed. Adrenal Steroid Antagonism. Berlin, Germany: Gruyter; 1984:77-101
6. Slayden OD, Chwalisz K, Brenner RM. Reversible suppression of menstruation with progesterone antagonists in rhesus macaques. Hum Reprod 2001;16:1562-1574
7. Gainer E, Ulmann A. Pharmacologic properties of CDB (VA)-2914. Steroids 2003;68:1005-1011
8. Elger W, Bartley J, Schneider B, et al. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-723
9. Chwalisz K, Brenner RM, Fuhrmann U, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators (PRMs) on the endometrium. Steroids 2000;65:741-751
10. Wolf JP, Hsiu JG, Anderson TL, et al. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 1989;52:1055-1060
11. Slayden OD, Zelinski-Wooten MB, Chwalisz K, Stouffer RL, Brenner RM. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod 1998;13:269-277
12. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996;81:1933-1939
13. Grow DR, Reece MT, Hsiu JG, et al. Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. Fertil Steril 1998;69:936-943
14. Cameron ST, Critchley HOD, Thong KJ, et al. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996;11:2518-2526
15. Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70
16. Zelinski-Wooten MB, Chwalisz K, Iliff SA, et al. A chronic, low dose regimen of the antiprogestin ZK 137 316 prevents pregnancy in rhesus monkeys. Hum Reprod 1998;13:2132-2138
17. Borman SM, Schwinof KM, Niemeyer C, et al. Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment. Hum Reprod 2003;18:69-76
18. Demanno B, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-1032
19. Chwalisz K, Larsen L, McCrary K, Edmonds A. Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. J Soc Gynecol Investig 2004;11(suppl 2):320-321
20. Bardon S, Vignon F, Montcourrier P, Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 1987;47:1441-1448
21. Murphy AA, Zhou MH, Malkapuram S, et al. RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000;74:1014-1019
22. Parthasarathy S, Morales AJ, Murphy AA. Antioxidant: a new role for RU-486 and related compounds. J Clin Invest 1994;94:1990-1995
23. Han S, Sidell N. RU486-Induced growth inhibition of human endometrial cells involves the nuclear factor-kappaB signaling pathway. J Clin Endocrinol Metab 2003;88:713-719
24. Chwalisz K, Stöckemann K, Fritzemeier K-H, Fuhrmann U. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum Reprod Update 1998;4:570-583
25. Grody MH, Lampe EH, Masters WH. Estrogen-androgen substitution therapy in the aged female. Obstet Gynecol 1953; 2:36-45
26. Okon MA, Laird SM, Tuckerman EM, Li T-C. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril 1998;69:682-690
27. Rose GL, Dowsett M, Mudge JE, White JO, Jeffcoate SL. The inhibitory effects of danazol, danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in vitro. Fertil Steril 1988;49:224-228
28. Tuckerman EM, Okon MA, Li T-C, Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril2000;74:771-779
29. Critchley H, Wang H, Jones R, et al. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 1998;13:1218-1224
30. Critchley HOD, Brenner RM, Henderson TA, et al. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab 2001;86:1370-1378
31. Cameron ST, Critchley HOD, Buckley CH, Kelly RW, Baird DT. Effect of two antiprogestins (mifpristone and onapristone) on endometrial factors of potential importance for implantation. Fertil Steril 1997;67:1046-1053
32. Slayden OD, Nayak NR, Burton KA, et al. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab 2001;86:2668-2679
33. Narvekar N, Cameron S, Critchley H, et al. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004;89:2491-2497
34. Slayden OD, Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab 2003;88:946-949
35. Cooke PS, Buchanan DL, Young P, et al. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA 1997;94:6535-6540
36. McClellan MC, Rankin S, West NB, Brenner RM. Estrogen receptors, progestin receptors and DNA synthesis in the macaque endometrium during the luteal-follicular transition. J Steroid Biochem Mol Biol 1990;37:631-641
37. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA. Stimulation of androgen-regulated transaction by modulators of protein phosphorylation. Endocrinology 1994;135:1359-1366
38. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 2002;66:297-304
39. Ajossa S, Guerriero S, Paoletti AM, Orru M, Melis GB. The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. Fertil Steril 2002;77:1136-1140
40. de Ziegler D, Bessis R, Frydman R. Vascular resistance of uterine arteries: physiological effects of estradiol and progesterone. Fertil Steril 1991;55:775-779
41. Reinsch RC, Murphy AA, Morales AJ, Yen SSC. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol 1994;170:1623-1628
42. Charmandari E, Calis KA, Keil MF, et al. Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2002;87:3197-3200
43. Baird DT, Brown A, Critchley HO, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-68
44. Eisinger S, Meldrum S, Fiscella K, le Roux H, Guzick D. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101:243-250
45. Croxatto HB, Kovács L, Massai R, et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998;13:793-798
46. Murphy A, Kettel L, Morales A, et al. Endometrial effects of long-term low-dose administration of RU486. Fertil Steril 1995;63:761-766
47. Newfield R, Spitz I, Isacson C, New M. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 2001;54:399-404
48. Bamberger AM, Milde-Langosch K, Loning T, Bamberger CM. The glucocorticoid receptor is specifically expressed in the stromal compartment of the human endometrium. J Clin Endocrinol Metab 2001;86:5071-5074
49. Henderson TA, Saunders PT, Moffett-King A, Groome NP, Critchley HO. Steroid receptor expression in uterine natural killer cells. J Clin Endocrinol Metab 2003;88:440-449
50. Brenner RM, Slayden OD, Rodgers WH, et al. Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum Reprod 2003;18:1185-1193